FDA On Trial Registries: Manufacturers Should Steer Clear Of Claims
Executive Summary
Manufacturers should be cautious about drawing explicit conclusions about the outcome of clinical trials posted on public registries, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams told a Pharma Audioconference Oct. 26
You may also be interested in...
AstraZeneca Crestor Ad Defends Safety, Re-Asserts Superiority Claims
AstraZeneca's full-page ads responding to questions about the safety of Crestor (rosuvastatin) repeat the company's claim that the drug is more effective at lowering cholesterol than other statins
AstraZeneca Crestor Ad Defends Safety, Re-Asserts Superiority Claims
AstraZeneca's full-page ads responding to questions about the safety of Crestor (rosuvastatin) repeat the company's claim that the drug is more effective at lowering cholesterol than other statins
Off-Label Promotion Remains Vulnerable To Prosecution, DoJ Says
The information dissemination provisions in the FDA Modernization Act do not provide "carte blanche" for manufacturers to promote drugs off-label, the Department of Justice said in a recent letter to the Washington Legal Foundation